Complete financial analysis of IN8bio, Inc. (INAB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of IN8bio, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- China Kings Resources Group Co.,Ltd. (603505.SS) Income Statement Analysis – Financial Results
- HELLA GmbH & Co. KGaA (HLE.SW) Income Statement Analysis – Financial Results
- Shenzhen Longli Technology Co.,Ltd (300752.SZ) Income Statement Analysis – Financial Results
- Sapphire Foods India Limited (SAPPHIRE.BO) Income Statement Analysis – Financial Results
- Stanrose Mafatlal Investments and Finance Limited (STANROS.BO) Income Statement Analysis – Financial Results
IN8bio, Inc. (INAB)
About IN8bio, Inc.
IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation. It also develops INB-400 and INB-300 that is in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 2.50M | 1.10M | 251.00K | 96.00K | 96.00K | 96.00K |
| Gross Profit | -2.50M | -1.10M | -251.00K | -96.00K | -96.00K | -96.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 16.83M | 14.06M | 7.35M | 5.38M | 2.36M | 581.00K |
| General & Administrative | 13.51M | 14.46M | 7.31M | 3.18M | 2.71M | 1.42M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 13.51M | 14.46M | 7.31M | 3.18M | 2.71M | 1.42M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -63.00K |
| Operating Expenses | 30.34M | 28.52M | 14.65M | 8.56M | 5.07M | 2.00M |
| Cost & Expenses | 30.34M | 28.52M | 14.65M | 8.56M | 5.07M | 2.00M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 14.00K |
| Depreciation & Amortization | 1.83M | 1.10M | 251.00K | 96.00K | 96.00K | 96.00K |
| EBITDA | -28.50M | -27.42M | -14.40M | -8.47M | -5.04M | -1.97M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -30.34M | -28.52M | -14.65M | -8.56M | -5.13M | -2.00M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 330.00K | 0.00 | 0.00 | 0.00 | 0.00 | -77.00K |
| Income Before Tax | -30.01M | -28.52M | -14.65M | -8.56M | -5.13M | -2.08M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -1.10M | 551.44K | -118.30K | -68.00K | -63.00K |
| Net Income | -30.01M | -27.42M | -14.65M | -8.56M | -5.13M | -2.08M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.00 | -1.31 | -0.78 | -0.44 | -0.27 | -0.34 |
| EPS Diluted | -1.00 | -1.31 | -0.78 | -0.44 | -0.27 | -0.34 |
| Weighted Avg Shares Out | 29.86M | 20.97M | 18.78M | 19.35M | 19.35M | 6.17M |
| Weighted Avg Shares Out (Dil) | 29.86M | 20.97M | 18.78M | 19.35M | 19.35M | 6.17M |
IN8bio Presents Positive Data Update from Induced Pluripotent Stem Cell (iPSC) Platform at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
NEW YORK, Nov. 03, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today presented new positive preclinical data from its induced pluripotent stem cell (iPSC) gamma-delta T cell...
IN8bio to Present New Positive Data from Phase 1 Trial of INB-100 at 2023 American Society of Hematology (ASH) Annual Meeting
NEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced an abstract detailing new, positive data from the Phase 1 investigator-sponsored trial of INB-100 in patients...
IN8bio to Participate at the 2023 Truist Securities BioPharma Symposium
NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced William Ho, CEO and co-founder, will participate in 1x1 meetings at the Truist Securities...
IN8bio Completes Dose Escalation in Phase 1 Trial of INB-100, a Potential First-in-Class Gamma-Delta T Cell Therapy for the Treatment of Leukemias, and Initiates Enrollment for the Phase 2 Trial of INB-400 in Newly Diagnosed Glioblastoma
NEW YORK, Oct. 12, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced the completion of enrollment in the Phase 1 study of INB-100 in leukemia patients...
IN8bio Announces Presentations at the Society for Immunology of Cancer (SITC) 38th Annual Meeting
NEW YORK, Sept. 29, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced two poster presentations reporting positive data at the Society for Immunotherapy of Cancer's (SITC)...
IN8bio to Host Research & Development Day on its Gamma-Delta T cell Therapies on Thursday, October 12, 2023 in New York City
NEW YORK, Sept. 26, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, is proud to announce its upcoming Research & Development Day on Thursday, October 12, 2023. The...
IN8bio to Participate at the 2023 Cantor Fitzgerald Global Healthcare Conference
NEW YORK, Sept. 20, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced William Ho, CEO and co-founder, will participate in a panel presentation at the 2023...
IN8bio Strengthens Intellectual Property Portfolio with Newly Granted Global Patents
NEW YORK, Sept. 19, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced significant updates to its foundational IP portfolio. The company was recently granted patents around...
IN8bio to Participate at the H.C. Wainwright 25th Annual Global Investment Conference
NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced William Ho, CEO and co-founder, will participate in a fireside chat at the H.C....
IN8bio to Present at the H.C. Wainwright Immune Cell Engager Virtual Conference
NEW YORK, Aug. 15, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced William Ho, CEO and co-founder, will participate in a fireside chat at the H.C....
Source: https://incomestatements.info
Category: Stock Reports